Loading organizations...
§ Venture Capital · Shanghai, Shanghai, China
Trend Investment Group operates as a venture capital firm based in Shanghai, China. The firm deploys capital across seed, early-stage, and later-stage rounds, primarily focusing on the dynamic healthcare and technology sectors. Its investment strategy supports promising companies demonstrating strong potential for growth and innovation within these critical industries.
Established in 2019 within Shanghai's competitive ecosystem, Trend Investment Group positioned itself to capitalize on rapid technological advancements and market opportunities. Its inception reflects increased private investment targeting high-growth sectors. Specific founder details or initial catalytic insights are not publicly available through accessible channels.
The firm's clientele comprises founders of innovative startups in both healthcare and technology, seeking financial backing and strategic partnership. Trend Investment Group's vision centers on cultivating significant advancements by providing essential capital and support. It aims to contribute to cutting-edge solutions, shaping the future landscape of global healthcare and technology.
Trend Investment Group has 4 tracked investments across 4 companies. The latest tracked deal is $4.7M Seed in Senisca in March 2024.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Mar 18, 2024 | Senisca | $4.7M Seed | — | APEX Ventures, Allan Weiner, Harry Robb, Richard Haycock, R42 Group |
| Oct 2, 2023 | Mogrify | $10.0M Series A Extension | Tadayoshi Hirata, Alastair Kilgour | Jonathan Milner, Ahren Innovation Capital |
| May 1, 2021 | Astrocyte Pharmaceuticals | $6.0M Series A | Boston Harbor Angels, Good Growth Capital | DeepWork Capital, SAM Goldberger, Astia Angels, Band OF Angels, Berkeley Angel Network, CR, Dreamers Startup Ventures, Kyto Technology & Life Science, Life Science Angels, Mass Medical Angels, MID Atlantic BIO Angels, Portfolia, Reno Seed Fund, Sidecar Angels, ZHI GAO Holding |
| Apr 25, 2017 | EpimAb Biotherapeutics | $25.0M Series A | — | 3E Bioventures Capital, MIN CUI |